The World Health Organization warned that artificial sweeteners, used to replace sugar in a vast range of products, do not help in losing weight and can have serious health effects.
According to the United Nations health agency, a systematic review of available evidence "suggests that use of non-sugar sweeteners (NSS) does not confer any long-term benefit in reducing body fat in adults or children.
In addition, results from the review suggest that the long-term use of NSS could increase the risk of type 2 diabetes, cardiovascular diseases, and mortality in adults.
The WHO's director for nutrition and food safety, Francesco Branca, stressed that replacing ordinary sugar with artificial sweeteners "does not help with weight control in the long term".
He added that NSS are not essential dietary factors and have no nutritional value.
The WHO said its new recommendation applied to everyone except individuals with pre-existing diabetes.
It includes all synthetic and naturally occurring or modified sweeteners not classified as sugars found in manufactured foods and beverages or sold on their own to be added to products by consumers.
Among the most widely used sweeteners are acesulfame K, aspartame, advantame, cyclamates, neotame, saccharin, sucralose, stevia, and stevia derivatives, it said.


Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
U.S. Stock Futures Edge Higher as Tech Rout Deepens on AI Concerns and Earnings
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



